NEW YORK (GenomeWeb) – A high-throughput, modular, and scalable, molecular diagnostics solution from Becton Dickinson has received CE-IVD certification and is now available for sale in Europe, BD announced today.
The BD Cor will be initially available with the firm's BD Onclarity HPV assay that detects and genotypes 14 high-risk human papillomaviruses. The Cor system enables processing of HPV tests directly from liquid-based cytology tubes, replacing manual aliquot steps.
The Cor system is fully automated and has on-board capacity for reagents and samples to provide six to eight hours of system processing, "eliminating multiple technologist interactions per shift," according to BD.
"The launch of the BD COR System is an important milestone on our molecular diagnostics roadmap allowing us to offer preanalytical automation and high throughput molecular testing to our largest laboratory customers," Dave Hickey, president of Diagnostic Systems at BD said.
The company said it plans to continue seeking regulatory authorizations to sell the BD Cor System around the world while expanding the content menu in infectious diseases.
Competing systems in the high-throughput, fully-automated molecular diagnostics arena currently include the Roche Cobas 6800 and 8800, Abbott Alinity m, NeuMoDx 288 Molecular System, and the Hologic Panther Trax system.